平特五不中

Please note: The Research + Innovation office will be closed for the holidays from noon on December 24 through January 2nd, inclusive. 鉂勶笍 Veuillez noter que le bureau de la Recherche et de l'Innovation sera ferm茅 pour les vacances du 24听d茅cembre 脿 midi jusqu鈥檃u 2听janvier inclus.

News

Novel, dual-targeted small molecule inhibitor of PKC and Aurora A kinase against cancer

Published: 10 October 2019

Invention 14075

Novel, dual-targeted small molecule inhibitor of PKC and Aurora A kinase against cancer

A small molecule inhibitor of protein kinase c and aurora a kinase in cancer models has been produced at 平特五不中.

Market Need

In cancer progression, tumors alter a number of cellular functions such as mobility, cell death, and proliferation. Two proteins that are commonly associated with some of these cellular pathways in tumor progression are aurora A kinase and protein kinase C. Aurora A kinase controls cell cycle progression and mitosis by interacting with different proteins. Protein kinase C regulates multiple features of tumor growth, including proliferation, survival, differentiation, and motility. Since even combination therapy often develops drug resistance, there is a great need for an inhibitor that targets multiple pathways.

Technology Summary

This technology is a small molecule inhibitor that is able to selectively target both Protein kinase C and Aurora A kinase in low nanomolar ranges. In pre-clinical studies, this inhibitor was found to have broad in vitro anti-proliferative and anti-invasive activities in human and mouse cancer models. These orally available molecules have proven effective in breast, pancreatic, and renal cancer models. Based on genome-wide profiling studies and functional assays, this drug has also been shown to have a unique mechanism affecting cancer cell differentiation.

Advantages

  • Molecules are oral therapeutic agents
  • Target 2 common metastatic kinases
  • Could be good for combination therapy since it has a unique mechanism affecting cancer cell differentiation

Patent Status

Filed US

Back to top